Staar Surgical Co. Stock
€43.86
Your prediction
Staar Surgical Co. Stock
Pros and Cons of Staar Surgical Co. in the next few years
Pros
Cons
Performance of Staar Surgical Co. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | 0.640% | -0.569% | 27.389% | -31.985% | 50.603% | -60.488% | - |
Orasure Tech | -0.980% | 4.508% | -11.304% | -18.400% | -31.544% | -36.928% | -40.028% |
scPharmaceuticals | -7.800% | 9.000% | -7.627% | -51.556% | -24.174% | -20.727% | - |
SI-BONE Inc | -2.140% | -0.709% | -0.709% | -26.702% | -26.316% | -51.049% | - |
Comments
News
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today